65th ASH Annual Meeting & Exposition

Preview Day on the Virtual Platform

Events

Preview Day on the Virtual Platform

Events

Registration at the Airport (for in-person participants)

Events

Registration at the Convention Center (for in-person participants)

Events

Registration at the Airport (for in-person participants)

Events

Advances in the Treatment Paradigm of Myeloid Malignancies: From Biology to Clinical Practice

Friday Satellite Symposia

Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Friday Satellite Symposia

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-part CME-accredited Symposia Series)

Friday Satellite Symposia

Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care with Team-Based Diagnosis and Treatment for Lower- and Higher-Risk Disease

Friday Satellite Symposia

Medical Crossfire: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies

Friday Satellite Symposia

Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today

Friday Satellite Symposia

Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options

Friday Satellite Symposia

Learn, Engage, and Relax in ASH Central (for in-person participants)

Events

Registration at the Convention Center (for in-person participants)

Events

Registration at the Grand Hyatt (for in-person participants)

Events

Registration at the Marriott Marquis (for in-person participants)

Events

Training Program Directors Workshop (for in-person participants)

Special-Interest Sessions

A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes

Friday Satellite Symposia

An MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes

Friday Satellite Symposia

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Diffuse Large B-Cell Lymphoma (Part 2 of a 4-part CME-accredited Symposia Series)

Friday Satellite Symposia

CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Evaluating the Evidence for Optimal Integration

Friday Satellite Symposia

Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management

Friday Satellite Symposia

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

Friday Satellite Symposia

Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-cell Lymphoma

Friday Satellite Symposia

Medical Crossfire: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL

Friday Satellite Symposia

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

Friday Satellite Symposia

More Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia

Friday Satellite Symposia

Multiple Myeloma: Clinical Challenges for the Community Clinician

Friday Satellite Symposia

Optimizing Myelofibrosis Management With Current and Emerging Therapies

Friday Satellite Symposia

Reimagining Outcomes in Hemophilia: Improving Efficacy and Reducing Treatment Burden with High-Sustained Factor and Non-Factor Replacement Therapies

Friday Satellite Symposia

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

Friday Satellite Symposia

Untangling Amyloidosis 2023: Diagnosis, Prognosis, Selection of Individualized Therapy, and Management of Difficult Clinical Complications

Friday Satellite Symposia

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

Scientific Workshops

Scientific Workshop on Myeloid Development

Scientific Workshops

Scientific Workshop on Hematology and Aging

Scientific Workshops

Scientific Workshop on the Interplay between Coagulation and Malignancy

Scientific Workshops

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer- From Worms to Patients

Scientific Workshops

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies

Scientific Workshops

Scientific Workshop on Viruses in Hematology: Emerging Challenges and Therapeutic Vulnerabilities

Scientific Workshops

Scientific Workshop on Defining Goals and Utilizing Tools for Enhancing Diversity, Equity and Inclusion (DEI) in Clinical Trials in Hematology

Scientific Workshops

Scientific Workshop on Diagnostic Techniques in Classical and Malignant Hematology

Scientific Workshops

Achieving ''Next-Level'' Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

Friday Satellite Symposia

Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease

Friday Satellite Symposia

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

Friday Satellite Symposia

Advancing cTTP Care Through Integration of the Latest Clinical Evidence

Friday Satellite Symposia

AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches

Friday Satellite Symposia

Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome

Friday Satellite Symposia

An Expert Guide to What's New and What''s Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma

Friday Satellite Symposia

A Rare Day in the Community Hematology Clinic: Interesting Cases in Classical Hematology

Friday Satellite Symposia

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia (Part 3 of a 4-part CME-accredited Symposia Series)

Friday Satellite Symposia

Case Challenges in Myelofibrosis for the Community Clinician

Friday Satellite Symposia

Changing the Path of Myelofibrosis: Envisioning a Brighter Future for Our Patients

Friday Satellite Symposia

Complement Wheel: Optimizing Care for Patients with aHUS, HSCT-TMA, and PNH

Friday Satellite Symposia

Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients' Lifespans

Friday Satellite Symposia

Putting Your Stamp on the Next Generation of Care in CML: Improving Outcomes from Frontline to R/R Treatment Settings

Friday Satellite Symposia

Real-World Applications of Asparaginase Formulations in ALL and LBL from Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care

Friday Satellite Symposia

Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents

Friday Satellite Symposia

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma (Part 4 of a 4-part CME-accredited Symposia Series)

Friday Satellite Symposia

Evolving Paradigms: Novel Approaches and Best Practices for Hodgkin Lymphoma

Friday Satellite Symposia

How Do We Treat GvHD Today... And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease

Friday Satellite Symposia

ASH Yoga (for in-person participants)

ASH Wellness Studio

Learn, Engage, and Relax in ASH Central (for in-person participants)

Events

Registration at the Convention Center (for in-person participants)

Events

Registration at the Grand Hyatt (for in-person participants)

Events

Registration at the Marriott Marquis (for in-person participants)

Events

Acquired Hemophilia A Diagnosis and Management (for in-person participants)

How I Treat: Bringing Science to Clinical Dilemmas

Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) (for in-person participants)

How I Treat: Bringing Science to Clinical Dilemmas

Advances in Myeloproliferative Neoplasms Affecting Management (for in-person participants)

How I Treat: Bringing Science to Clinical Dilemmas

Coffee and Collaboration in ASH Central (for in-person participants)

Events

Co-Operativity in the Pathogenesis of Myeloid Malignancies (For In-person Participants)

Meet the Scientist

Genome Engineering for Enhanced Blood Cancer Immunotherapy (For In-person Participants)

Meet the Scientist

Hematologists and the Care of Pregnant Women (for in-person participants)

How I Treat: Bringing Science to Clinical Dilemmas

Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle (For In-person Participants)

Meet the Scientist

Iron and Heme in Stem Cell Maintenance and Erythropoiesis (For In-person Participants) CANCELLED

Meet the Scientist

Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies (For In-person Participants)

Meet the Scientist

Patients with Acute Myeloid Leukemia (for in-person participants)

How I Treat: Bringing Science to Clinical Dilemmas

Coffee Break in Poster Hall (for in-person participants)

Events

Outcome Disparities in Hematologic Diseases: The Importance of Social Determinants of Health

Health Equity Studio

Poster Session I - Viewing

Events

What's Restoring You? (for in-person participants)

ASH Wellness Studio

An Oasis in Chaos (for in-person participants)

ASH Wellness Studio

Acquired Hemophilia A Diagnosis and Management

Education Program

Are We Personalizing MDS Therapy in 2023?

Education Program

CAR T Cells in ALL: Bridge or Definitive Therapy?

Education Program

How Do We Calibrate Cellular Therapy for Lymphoma in 2023?

Education Program

Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes

Scientific Program

Next Generation of Gene-Based Therapies for Bleeding Disorders

Scientific Program

The Evolution of Multiple Myeloma: From Inside-Out

Scientific Program

What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?

Education Program

101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Emerging Gene Regulatory Mechanisms in Erythroid Differentiation

Oral and Poster Abstracts

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Emerging Therapies for Sickle Cell Disease

Oral and Poster Abstracts

321. Coagulation and Fibrinolysis: Basic and Translational: Coagulation Protein: Molecular Insights and Molecular Therapies

Oral and Poster Abstracts

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Out of the Box: Acquired, Vascular and Other Neglected Bleeding Disorders

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Inflammation, Metabolism, and Stress

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Mechanisms of Acute Lymphoblastic Leukemia Development and Progression

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Upcoming Therapies in Newly Diagnosed and Relapsed/Refractory AML

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Risk Refinement and Therapy Response

Oral and Poster Abstracts

627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Rare Myeloproliferative Neoplasms: Unveiling Promising Pathways and Novel Therapies

Oral and Poster Abstracts

641. Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Determinants of CLL and Richter Transformation

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment

Oral and Poster Abstracts

652. Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications

Oral and Poster Abstracts

703. Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights

Oral and Poster Abstracts

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Improving Outcomes by Reducing Transplant-Related Complications

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Novel Targets in Blood Disorders

Oral and Poster Abstracts

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Reading the Blood: Generative and Discriminative AI in Hematology

Oral and Poster Abstracts

902. Health Services and Quality Improvement – Lymphoid Malignancies: Making a Splash In Outcomes Data

Oral and Poster Abstracts

904. Outcomes Research – Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric Patients

Oral and Poster Abstracts

Special Session on Sickle Cell Disease Centers

Special-Interest Sessions

Meet the Blood Advances Editors (for in-person participants)

Blood Journals Studio

Community Partnerships: An Essential Component to Advance Health Equity

Health Equity Studio

Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work

Blood Journals Studio

Live Music and Outdoor Lunch Seating (for in-person participants)

Events

Open Time for Lunch

Events

Exhibits Open

Events

Fix the Way You Sit (for in-person participants)

ASH Wellness Studio

ASH Grassroots Network Lunch

Special-Interest Sessions

Career Development Lunch

Trainee Activities and Services

Blood Presents: How to get Published in a Peer Review Journal

Special-Interest Sessions

Life-Saving Lessons from Plant-Based Eaters (for in-person participants)

ASH Wellness Studio

A Proven CAR T Cell Therapy With Extensive Real-World Experience For RRMM

Product Theaters

BTK Mutations and the Emergence of Treatment Resistance: Changing the CLL Landscape

Industry Theaters

COVID-19: Protecting Vulnerable Populations

Industry Theaters

Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types

Product Theaters

Quality of Life, Burden of Illness, and Treatment Burden in Paroxysmal Nocturnal Hemoglobinuria: A Current Perspective on C5 Inhibitors

Industry Theaters

The FIRST and ONLY Therapy Approved for Adults with Indolent Systemic Mastocystosis (ISM)

Product Theaters

Feel Better in Your Body (for in-person participants)

ASH Wellness Studio

Ham-Wasserman Lecture

General Sessions

Galapagos' 7 Day Vein-to-Vein Point-of-Care CAR-T Manufacturing Model

Company Showcases

Showcase on Galleri, a multi-cancer early detection test

Company Showcases

Coffee Break in Exhibit Hall (for in-person participants)

Events

How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective

Health Equity Studio

Finding Stillness in the Busyness (for in-person participants)

ASH Wellness Studio

The Real Purpose of Your Purpose (for in-person participants)

ASH Wellness Studio

Alternative Immune Effector Cells

Scientific Symposia

Co-Operativity in the Pathogenesis of Myeloid Malignancies

Scientific Program

Emerging Methodologies to Investigate Platelet Biology

Scientific Program

How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?

Education Program

Inherited Bone Marrow Failure Syndromes - From Pediatrics to Adult

Education Program

Ongoing Challenges in the Management of VTE

Education Program

Spatial Genomic & Epigenomic Profiling in Hematology

Scientific Program

Transfusion Support in Sickle Cell Disease

Education Program

101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Erythropoiesis in Stress and Disease

Oral and Poster Abstracts

114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Hot Topics in Clinical Care and Genomic Factors

Oral and Poster Abstracts

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Decoding the Complex Landscape of Human Immunity: Insights From Genetic Mutations to Cellular Heterogeneity

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Uses of Approved Therapeutic Agents

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc.

Oral and Poster Abstracts

622. Lymphomas: Translational – Non-Genetic: Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma

Oral and Poster Abstracts

624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Szary and Hodgkin Lymphomas

Oral and Poster Abstracts

627. Aggressive Lymphomas: Clinical and Epidemiological: Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas

Oral and Poster Abstracts

637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment Options and Decision Making in Low Risk MDS

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation

Oral and Poster Abstracts

653. Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma

Oral and Poster Abstracts

654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines–The Spectrum of Plasma Cell Disorders

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Expanding Disease Targets for CAR-T Cell Therapies

Oral and Poster Abstracts

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Long-Term Survival and Survivorship From Clinical Trials And Observations

Oral and Poster Abstracts

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology

Oral and Poster Abstracts

901. Health Services and Quality Improvement – Non-Malignant Conditions: Sickle Cell Disease Across the Spectrum

Oral and Poster Abstracts

902. Health Services and Quality Improvement – Lymphoid Malignancies: Innovative Care in CAR-T Therapy

Oral and Poster Abstracts

903: Health Services and Quality Improvement – Myeloid Malignancies: From Blood to Bombs: Identifying and Addressing Barriers to Care for Myeloid Malignancies

Oral and Poster Abstracts

905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Lymphoma/CLL: Biomarkers, Dosing Strategies, and Big-Data

Oral and Poster Abstracts

Distinguished Abstract Achievement Award Ceremony (for in-person participants)

Blood Journals Studio

Special Symposium on Quality - Identifying and Addressing Underuse in Hematologic Care

Special-Interest Sessions

Genetic Engineering of T Cells and CD34+ HSPCs using RNA-Lipid Nanoparticle for Cell and Gene Therapies

Company Showcases

Reimagining Cancer Care at Syndax: Clinical Development of Targeted Therapies

Company Showcases

Coffee Break in Exhibit Hall (for in-person participants)

Events

Using Research to Advance Equity in the LGBTQIA+ Space

Health Equity Studio

Workday Tension Timeout (for in-person participants)

ASH Wellness Studio

Eating With a Full Mind or Mindfully (for in-person participants)

ASH Wellness Studio

ASH Poster Walk on Hemostasis and Thrombosis hosted by Blood VTH (For In-person Participants)

ASH Poster Walks

Graft Versus Host Disease: Is an Ounce of Prevention Worth a Pound of Cure?

Education Program

Hematologic Toxicity of Immunotherapies

Education Program

How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?

Education Program

Iron and Heme in Stem Cell Maintenance and Erythropoiesis

Scientific Program

Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis

Scientific Program

Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis

Scientific Program

The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression.

Scientific Program

Why Am I Getting Paged at 2AM? Microangiopathic Emergencies

Education Program

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease

Oral and Poster Abstracts

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias

Oral and Poster Abstracts

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Beyond the Numbers: Non-Factor Factors in Bleeding Disorder Care

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Immunologic and Metabolic Biomarkers of Disease Control

Oral and Poster Abstracts

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL

Oral and Poster Abstracts

624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in Treating T Cell Lymphomas

Oral and Poster Abstracts

627. Aggressive Lymphomas: Clinical and Epidemiological: Outcomes of Relapsed/Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents

Oral and Poster Abstracts

636. Myelodysplastic Syndromes – Basic and Translational: Molecular Drivers and Therapeutic Implications

Oral and Poster Abstracts

637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatments and Outcome Predictions in High Risk MDS

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment

Oral and Poster Abstracts

652. Multiple Myeloma: Clinical and Epidemiological: Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: GVHD, Intestinal Immunity, and the Gut Microbiome

Oral and Poster Abstracts

703. Cellular Immunotherapies: Basic and Translational: Cellular Immunotherapy: Preclinical and Translational Insights

Oral and Poster Abstracts

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Prediction and Management of CAR-T Cell Related Toxicity

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Basic and Translational: Optimizing Post-Transplant Outcomes

Oral and Poster Abstracts

901. Health Services and Quality Improvement – Non-Malignant Conditions: Access to Quality Care in Classical Hematology

Oral and Poster Abstracts

903. Health Services and Quality Improvement – Myeloid Malignancies: Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies

Oral and Poster Abstracts

905. Outcomes Research – Lymphoid Malignancies: Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma

Oral and Poster Abstracts

906. Outcomes Research – Myeloid Malignancies: Risk Factors and Health Disparities

Oral and Poster Abstracts

Joint Session: Lymphomagenesis - What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies

Scientific Program

Joint Session: Ontogeny and Myeloid Disorders of Childhood

Scientific Program

Meet the Blood VTH Editor-in-Chief (for in-person participants)

Blood Journals Studio

Poster Session I - Presentations (for in-person participants)

Events

Welcome Reception in Poster Hall (for in-person participants)

Events

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Oral and Poster Abstracts

102. Iron Homeostasis and Biology: Poster I

Oral and Poster Abstracts

112. Thalassemia and Globin Gene Regulation: Poster I

Oral and Poster Abstracts

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I

Oral and Poster Abstracts

114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

201. Granulocytes, Monocytes, and Macrophages: Poster I

Oral and Poster Abstracts

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I

Oral and Poster Abstracts

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I

Oral and Poster Abstracts

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

321. Coagulation and Fibrinolysis: Basic and Translational: Poster I

Oral and Poster Abstracts

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-Related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

401. Blood Transfusion: Poster I

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging and Inflammation: Poster I

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: Poster I

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Poster I

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Poster I

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Poster I

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I

Oral and Poster Abstracts

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I

Oral and Poster Abstracts

618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Poster I

Oral and Poster Abstracts

622. Lymphomas: Translational – Non-Genetic: Poster I

Oral and Poster Abstracts

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I

Oral and Poster Abstracts

627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

636. Myelodysplastic Syndromes – Basic and Translational: Poster I

Oral and Poster Abstracts

637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I

Oral and Poster Abstracts

652. Multiple Myeloma: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I

Oral and Poster Abstracts

654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: Poster I

Oral and Poster Abstracts

703. Cellular Immunotherapies: Basic and Translational: Poster I

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I

Oral and Poster Abstracts

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I

Oral and Poster Abstracts

711. Cell Collection and Processing: Poster I

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Poster I

Oral and Poster Abstracts

731. Autologous Transplantation: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I

Oral and Poster Abstracts

801. Gene Therapies: Poster I

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Poster I

Oral and Poster Abstracts

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I

Oral and Poster Abstracts

901. Health Services and Quality Improvement – Non-Malignant Conditions: Poster I

Oral and Poster Abstracts

902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I

Oral and Poster Abstracts

903. Health Services and Quality Improvement – Myeloid Malignancies: Poster I

Oral and Poster Abstracts

904. Outcomes Research – Non-Malignant Conditions: Poster I

Oral and Poster Abstracts

905. Outcomes Research – Lymphoid Malignancies: Poster I

Oral and Poster Abstracts

906. Outcomes Research – Myeloid Malignancies: Poster I

Oral and Poster Abstracts

Promoting Minorities in Hematology (PMH) Oral Presentations: Room I (for in-person participants)

Special-Interest Sessions

Promoting Minorities in Hematology (PMH) Oral Presentations: Room II (for in-person participants)

Special-Interest Sessions

Promoting Minorities in Hematology (PMH) Oral Presentations: Room III (for in-person participants)

Special-Interest Sessions

Promoting Minorites in Hematology (PMH) MRI Anniversary Reception (for in-person participants)

Special-Interest Sessions

ASH Foundation Run/Walk

Events

Registration at the Convention Center (for in-person participants)

Events

Learn, Engage, and Relax in ASH Central (for in-person participants)

Events

Medical Educators Symposium

Special-Interest Sessions

APHEXDA (motixafortide): Learn about this new FDA approved treatment option

Product Theaters

A Treatment Option for Relapsed or Refractory Multiple Myeloma from Pfizer

Product Theaters

Cellular Therapy for Lymphoma (ticketed session for in-person participants)

How I Treat: Bringing Science to Clinical Dilemmas

Classical Hematology: Looking into the Future

Industry Theaters

Coffee and Collaboration in ASH Central (for in-person participants)

Events

Could there be a Link Between Autoimmune Cytopenias, Lymphadenopathy, and Splenomegaly? A Physician''s Perspective and a Patient''s Experience

Product Theaters

Early Management of Acute Promyelocytic Leukemia (APML) (ticketed session for in-person participants)

How I Treat: Bringing Science to Clinical Dilemmas

Energizing the Red Cell: Novel Therapies for Hereditary Hemolytic Anemias (ticketed session for in-person participants)

Meet the Scientist

Exploring Time Off Treatment with a BCL-2 Inhibitor

Product Theaters

Introducing CASGEVY (exagamglogene autotemcel)

Industry Theaters

Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes (ticketed session for in-person participants)

Meet the Scientist

Natural Killer Cells: A New Frontier for Cancer Immunotherapy (ticketed session for in-person participants)

Meet the Scientist

Ongoing Challenges in the Management of VTE (ticketed session for in-person participants)

How I Treat: Bringing Science to Clinical Dilemmas

Research in Complications Sickle Cell Disease (ticketed session for in-person participants)

Meet the Scientist

T-Cell Redirection Therapy for Multiple Myeloma (ticketed session for in-person participants)

How I Treat: Bringing Science to Clinical Dilemmas

The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression (ticketed session for in-person participants)

Meet the Scientist

Unveiling a Subcutaneous Therapy for 3L+ DLBCL

Product Theaters

Coffee Break in Poster Hall (for in-person participants)

Events

Systemic Racism in Hematology

Health Equity Studio

Poster Session II - Viewing

Events

How to Quiet the Mind Chatter (for in-person participants)

ASH Wellness Studio

Family First - 7 Steps to Living Well (for in-person participants)

ASH Wellness Studio

Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes: Too Early, Too Late, Just Right?

Education Program

Hemostasis in Patients With Severe Liver Disease

Education Program

How Do We Enhance Results in Rare Hematologic Malignancies?

Education Program

How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?

Education Program

The Impact of the Microbiota on Immunotherapy of Hematological Malignancies

Scientific Symposia

The Iron Revolution!

Education Program

Understanding Sickle Cell Pathophysiology

Scientific Symposia

What Are the Advances in Myeloproliferative Neoplasms Affecting Management?

Education Program

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Practice, Natural History, and Patient Reported Outcomes

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Cell Fate Decisions and Fitness

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Therapeutic Strategies and Cellular Mechanisms

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Strategies to Overcome Therapy Resistance in Myeloid Malignancies

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeted Therapy in Lymphoid Leukemias

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response

Oral and Poster Abstracts

622. Lymphomas: Translational – Non-Genetic: Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma

Oral and Poster Abstracts

626. Aggressive Lymphomas: Prospective Therapeutic Trials: Novel Therapies For Relapsed/Refractory Aggressive Lymphoma

Oral and Poster Abstracts

627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment to Best Outcomes: Find the Right Therapy for the Right Patient

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Treatment-Free Remission and Prognostication

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution

Oral and Poster Abstracts

703. Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Novel Conditioning Regimens for Myeloid Malignancies

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Emerging Insights in GVHD Immunobiology

Oral and Poster Abstracts

801. Gene Therapies: New Approaches From Bench to Bedside

Oral and Poster Abstracts

904. Outcomes Research – Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders

Oral and Poster Abstracts

905. Outcomes Research – Lymphoid Malignancies: Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology

Oral and Poster Abstracts

2023 ASH Guideline Implementation Champions

Special-Interest Sessions

Maternal Health: Fertility Preservation in Hematology Care

Special-Interest Sessions

Special Scientific Session on Race and Science: Bench to Bedside to the Community

Special-Interest Sessions

Joint Session: Genome Engineering for Enhanced Blood Cancer Immunotherapy

Scientific Program

Meet the Blood Editors (for in-person participants)

Blood Journals Studio

Exhibits Open

Events

Legally Intentional: Overcoming Barriers to Inclusion in the Hematology Workforce

Health Equity Studio

Complimentary Light Lunch in the Exhibit Hall (for in-person participants)

Events

Live Music and Outdoor Lunch Seating (for in-person participants)

Events

The Real Purpose of Your Purpose (for in-person participants)

ASH Wellness Studio

Blood Advances Presents: How to Peer Review a Scientific Paper

Special-Interest Sessions

Health Equity Rounds Lunch (for in-person participants)

Special-Interest Sessions

Trainee Didactic Session: A Road Less Traveled - Careers Outside of Academia

Trainee Activities and Services

Trainee Didactic Session: The International Trainee Journey

Trainee Activities and Services

ASH Clinicians in Practice (ACIP) Lunch - How Can We Provide Sustainable Care to Hematology Patients?

Special-Interest Sessions

Straight Spine, Big Smile (for in-person participants)

ASH Wellness Studio

A Complement Inhibitor for PNH

Product Theaters

A Discussion on a Treatment Option for Sickle Cell Disease

Product Theaters

Janssen invites you to learn about a treatment for adult patients with RRMM who have received at least four prior lines of therapy, including a PI, IMiD, and anti-CD38 monoclonal antibody

Product Theaters

Learn about an alternative treatment for certain B-cell malignancies. This program is sponsored by Lilly USA, LLC.

Product Theaters

Learn more about a new FDA-approved treatment, OJJAARA (momelotinib)

Product Theaters

Long-term Clinical Trial Results for a BTKi in the Treatment of CLL/SLL

Product Theaters

Treatment Options in Relapsed Refractory Multiple Myeloma: Clinical Data and Patient Cases

Product Theaters

Stress Doesn't Exist (for in-person participants)

ASH Wellness Studio

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis

Oral and Poster Abstracts

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Bleeding Disorder Management Throughout the Lifespan

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: Bone Marrow Microenvironment in Health and Disease

Oral and Poster Abstracts

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Progress Through Collaboration: Impactful Cooperative Efforts to Optimize Care for ALL

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Signaling Pathways and MRD in Lymphoma

Oral and Poster Abstracts

652. Multiple Myeloma: Clinical and Epidemiological: Outcomes, Choices and Predispositions

Oral and Poster Abstracts

654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis

Oral and Poster Abstracts

905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Myeloma: What's New?

Oral and Poster Abstracts

906. Outcomes Research – Myeloid Malignancies: Real-World Treatment Patterns and Outcomes

Oral and Poster Abstracts

ASH-EHA Joint Symposium

General Sessions

Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, and the ASH Award for Leadership in Promoting Diversity

General Sessions

Outcome Disparities in Hematologic Diseases: The Importance of Social Determinants of Health

Health Equity Studio

Simulcast of Anouncement of Awards and Plenary Scientific Session (for in-person participants)

Special-Interest Sessions

Simulcast of Anouncement of Awards and Plenary Scientific Session (for in-person participants)

Special-Interest Sessions

Simulcast of Anouncement of Awards and Plenary Scientific Session (for in-person participants)

Special-Interest Sessions

Plenary Scientific Session

General Sessions

Halia Therapeutics- Targeting the Chronic Inflammatory Bone Marrow Microenvironment

Company Showcases

Coffee Break in Exhibit Hall (for in-person participants)

Events

Community Partnerships: An Essential Component to Advance Health Equity

Health Equity Studio

The Greatest Medicine...The Right Tribe! (for in-person participants)

ASH Wellness Studio

Fix the Way You Sit (for in-person participants)

ASH Wellness Studio

ASH Poster Walk on the Progression of Clonal Hematopoiesis to Hematologic Neoplasms: Biology, Risk Stratification and Therapeutic Interventions hosted by Blood Neoplasia (For In-person Participants)

ASH Poster Walks

Debate: PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors?

Spotlight Sessions

Have We Optimized Therapy Yet for Patients with AML?

Education Program

Hematologists and the Care of Pregnant Women

Education Program

Hot Topics in Blood Donation: Donor Risks and Social Justice

Education Program

How Do We Tackle Remaining Clinical Challenges in CML?

Education Program

Immunometabolism as a Tool to Advance Cell Therapy

Spotlight Sessions

Tackling Greater Burden of Multiple Myeloma in African American Patients.

Spotlight Sessions

Where the Bench Meets the Bedside: Laboratory Correlates in Clinical Trials

Spotlight Sessions

112. Thalassemia and Globin Gene Regulation: Finding New Pathways to Treat Thalassemia

Oral and Poster Abstracts

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Pathophysiology of Sickle Hemoglobinopathies: From Mice to Humans

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT): Understanding Risk as a Potential Means to Improve Patient Care

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy From Clinical Trials

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies

Oral and Poster Abstracts

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Real World Outcomes and Treatment Approaches

Oral and Poster Abstracts

618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment

Oral and Poster Abstracts

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy

Oral and Poster Abstracts

624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in the Treatment of Hodgkin Lymphoma

Oral and Poster Abstracts

627. Aggressive Lymphomas: Clinical and Epidemiological: Aiming for the Right Target: Using CAR-T and Bispecifics in Aggressive Lymphomas

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Charting The Future Of MPN Therapies

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Myelofibrosis: New Therapeutic Frontiers

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States

Oral and Poster Abstracts

652. Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Innovative Approaches to GVHD Prevention and Treatment

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Use of Molecular Techniques for Risk Stratification

Oral and Poster Abstracts

901. Health Services and Quality Improvement – Non-Malignant Conditions: Raising the bar in Anemia, Bleeding, and Thrombotic Disorders

Oral and Poster Abstracts

905. Outcomes Research – Lymphoid Malignancies: Patient Reported Outcomes in Hematological Malignancies

Oral and Poster Abstracts

Blood and Beyond

Special-Interest Sessions

Systems-Based Hematology Education and Networking Session: Hematology E-Consultation

Special-Interest Sessions

Meet the Blood Neoplasia Editor-in-Chief (for in-person participants)

Blood Journals Studio

Poster Hall Reception (for in-person participants)

Events

Poster Session II - Presentations (for in-person participants)

Events

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II

Oral and Poster Abstracts

102. Iron Homeostasis and Biology: Poster II

Oral and Poster Abstracts

112. Thalassemia and Globin Gene Regulation: Poster II

Oral and Poster Abstracts

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II

Oral and Poster Abstracts

114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

201. Granulocytes, Monocytes, and Macrophages: Poster II

Oral and Poster Abstracts

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II

Oral and Poster Abstracts

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster II

Oral and Poster Abstracts

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

321. Coagulation and Fibrinolysis: Basic and Translational: Poster II

Oral and Poster Abstracts

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

401. Blood Transfusion: Poster II

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging and Inflammation: Poster II

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: Poster II

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Poster II

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Poster II

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Poster II

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II

Oral and Poster Abstracts

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II

Oral and Poster Abstracts

618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II

Oral and Poster Abstracts

621. Lymphomas: Translational—Molecular and Genetic: Poster II

Oral and Poster Abstracts

622. Lymphomas: Translational–Non-Genetic: Poster II

Oral and Poster Abstracts

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II

Oral and Poster Abstracts

627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

636. Myelodysplastic Syndromes—Basic and Translational: Poster II

Oral and Poster Abstracts

637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster II

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II

Oral and Poster Abstracts

652. Multiple Myeloma: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

653. Multiple Myeloma: Prospective Therapeutic Trials: Poster II

Oral and Poster Abstracts

654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: Poster II

Oral and Poster Abstracts

703. Cellular Immunotherapies: Basic and Translational: Poster II

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II

Oral and Poster Abstracts

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II

Oral and Poster Abstracts

711. Cell Collection and Processing: Poster II

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II

Oral and Poster Abstracts

731. Autologous Transplantation: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II

Oral and Poster Abstracts

801. Gene Therapies: Poster II

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Poster II

Oral and Poster Abstracts

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II

Oral and Poster Abstracts

901. Health Services and Quality Improvement - Non-Malignant Conditions: Poster II

Oral and Poster Abstracts

902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster II

Oral and Poster Abstracts

903. Health Services and Quality Improvement –Myeloid Malignancies: Poster II

Oral and Poster Abstracts

904. Outcomes Research—Non-Malignant Conditions: Poster II

Oral and Poster Abstracts

905. Outcomes Research—Lymphoid Malignancies: Poster II

Oral and Poster Abstracts

906. Outcomes Research—Myeloid Malignancies: Poster II

Oral and Poster Abstracts

ASH Yoga (for in-person participants)

ASH Wellness Studio

Wake Up To DEI Networking Breakfast (for in-person participants)

Special-Interest Sessions

Registration at the Convention Center (for in-person participants)

Events

Learn, Engage, and Relax in ASH Central (for in-person participants)

Events

Achieving Higher Factor VIII Levels in Hemophilia A

Product Theaters

An Advancement in Frontline DLBCL and A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma

Product Theaters

A new, first-in-class treatment for RRMM patients

Product Theaters

Coffee and Collaboration in ASH Central (for in-person participants)

Events

Hear from Novartis about a new treatment for adults with PNH

Product Theaters

Latest Advancement in Allogeneic Hematopoietic Cell Transplantation

Product Theaters

How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective

Health Equity Studio

E. Donnall Thomas Lecture and Prize

General Sessions

Poster Session III - Viewing

Events

Coffee Break in Exhibit Hall (for in-person participants)

Events

Using Research to Advance Equity in the LGBTQIA+ Space

Health Equity Studio

Meet the Blood Advances Editors (for in-person participants)

Blood Journals Studio

Exhibits Open

Events

What's Restoring You? (for in-person participants)

ASH Wellness Studio

Eating With a Full Mind or Mindfully (for in-person participants)

ASH Wellness Studio

Advances in Genomics: Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma

Spotlight Sessions

Energizing the Red Cell: Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias

Education Program

How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies

Education Program

Pre- and Post-Thrombus: Risk Factors of Clotting and Post-Thrombosis Syndrome

Scientific Program

201. Granulocytes, Monocytes, and Macrophages: Granulocytes, Monocytes and Disorders of Histocytes

Oral and Poster Abstracts

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Targeting platelet reactivity in thrombosis

Oral and Poster Abstracts

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Innovative Treatments for Immune Thrombocytopenia

Oral and Poster Abstracts

331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-Related Thrombotic/Vascular Disorders: Clinical and Epidemiological: New Frontiers in TTP: Diagnostic and Therapeutic Innovations

Oral and Poster Abstracts

401. Blood Transfusion: Advances in Transfusion Medicine

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Immune AA and VEXAS – Biology, Diagnosis and Treatment

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: RNA Splicing, Transcription, and Chromatin Dynamics

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis

Oral and Poster Abstracts

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Long-Term Outcomes for Children and Adults Diagnosed With AML/APL

Oral and Poster Abstracts

623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Treatment and Outcomes in MPNs

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström's Macroglobulinemia

Oral and Poster Abstracts

652. Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma

Oral and Poster Abstracts

703. Cellular Immunotherapies: Basic and Translational: Exploring Novel Platforms for Next-Gen CAR-Based Therapies

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Advancements in GVHD Management

Oral and Poster Abstracts

731. Autologous Transplantation: Clinical and Epidemiological: Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas: A Therapeutic Approach

Oral and Poster Abstracts

901. Health Services and Quality Improvement – Non-Malignant Conditions: Improving Care in Sickle Cell Disease Via Technologies and Medical Education

Oral and Poster Abstracts

AI in Hematology: Where Do You Stand in 2023?

Special-Interest Sessions

ASH-FDA Joint Symposium I: Targeted, Gene and Cellular Therapy - Recent Approvals in Non-Malignant Hematology

Special-Interest Sessions

ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults

Special-Interest Sessions

Junior Faculty Career Development Session

Special-Interest Sessions

Best Practices for Peer Review: ASH Clinical News interviews the Blood Advances Editors (for in-person participants)

Blood Journals Studio

Systemic Racism in Hematology

Health Equity Studio

The ABCs of Publishing for Authors: The Hematologist interviews the Blood Editors (for in-person participants)

Blood Journals Studio

Complimentary Light Lunch in the Exhibit Hall (for in-person participants)

Events

Live Music and Outdoor Lunch Seating (for in-person participants)

Events

Feel Better in Your Body (for in-person participants)

ASH Wellness Studio

An FDA approved treatment option for anemia in LR-MDS

Product Theaters

ASH Choosing Wisely® Campaign: 2023 ASH Choosing Wisely Champions

Special-Interest Sessions

CARVYKTI Product Summary for Healthcare Providers

Product Theaters

Emerging AstraZeneca Hematology Pipeline

Industry Theaters

Gilead and Kite Oncology Pipeline

Industry Theaters

In Pursuit of Healthier Red Blood Cells: The RISE UP Phase 2/3 Clinical Trial of Mitapivat in Sickle Cell Disease

Industry Theaters

Outcomes and Economic Impact of Treatment with CABLIVI (caplacizumab-yhdp)

Product Theaters

Trainee Didactic Session: Show Me the Money - Funding Your Research

Trainee Activities and Services

Trainee Didactic Session: What to Ask For in an Interview

Trainee Activities and Services

Workday Tension Timeout (for in-person participants)

ASH Wellness Studio

An Oasis in Chaos (for in-person participants)

ASH Wellness Studio

Legally Intentional: Overcoming Barriers to Inclusion in the Hematology Workforce

Health Equity Studio

Ernest Beutler Lecture and Prize

General Sessions

Coffee Break in Poster Hall (for in-person participants)

Events

Protective Power of Plants (for in-person participants)

ASH Wellness Studio

Factor XI - From Bleeding to Thrombosis

Spotlight Sessions

Interplay of Coagulation and Complement in Transfusion Medicine

Scientific Program

Managing Previvorship in Hematology: Clinical Approaches to CCUS and MBL

Spotlight Sessions

Multi-Omics Driven Precision Hematology

Scientific Symposia

Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL?

Education Program

What is a “Normal” Neutrophil Count? The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution

Spotlight Sessions

What Makes a Good Transplant Recipient? Putting the Puzzle Pieces Together

Education Program

Who are the Alternatives for Cellular Therapies? Engineering and Retargeting Other Effector Lymphocytes

Spotlight Sessions

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advances in Clinical Care and Implementation

Oral and Poster Abstracts

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Thrombocytopenia in Special Populations

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Genetics, Pregnancy, and Pediatrics: Advances in Venous Thromboembolism

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging and Inflammation: From Omics to Discoveries

Oral and Poster Abstracts

613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML – De Novo and Myelodysplasia-Related

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Optimal Frontline Treatment for ALL

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Refining Chemotherapy Regimens Plus/Minus MRD Evaluation to Optimize Outcomes in AML

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Deciphering Risk by Genetic and Epigenetic Features

Oral and Poster Abstracts

618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Novel Disease Subclassifications and Clinical Prognosis

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Insights into Lymphoma: Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics

Oral and Poster Abstracts

626. Aggressive Lymphomas: Prospective Therapeutic Trials: Initial treatment strategies in aggressive B Cell lymphomas

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Lineage Tracing and Novel Target Discovery

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions

Oral and Poster Abstracts

652. Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes

Oral and Poster Abstracts

703. Cellular Immunotherapies: Basic and Translational: Innovative T Cell Therapies for Unexplored Frontiers

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Improving CAR-T Therapies for B Cell Malignancies

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Modern Challenges in Transplantation

Oral and Poster Abstracts

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Image-Based Machine Learning in Hematology

Oral and Poster Abstracts

902. Health Services and Quality Improvement – Lymphoid Malignancies: Improving Processes and Outcomes in Plasma Cell Dyscrasias

Oral and Poster Abstracts

906. Outcomes Research – Myeloid Malignancies: Symptom Burden and Supportive Therapies

Oral and Poster Abstracts

ASH-FDA Joint Symposium II: Striking a Balance - Benefit-Risk in Drug Approvals

Special-Interest Sessions

Meet the Blood Editors (for in-person participants)

Blood Journals Studio

Alphabet Soup - Challenging Consults on the Pediatric Units

Education Program

Hematologists as Lifesavers: Inpatient Hematology Emergencies

Education Program

How Can We Manage High-Risk Hematologic Malignancies in the Community?

Education Program

Improving Outcomes for Individuals With Sickle Cell Disease: Are We Moving the Needle?

Education Program

102. Iron Homeostasis and Biology: Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis

Oral and Poster Abstracts

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Sickle Cell Treatment: Present and Future

Oral and Poster Abstracts

201. Granulocytes, Monocytes, and Macrophages: New Insights into Inherited and Acquired Neutropenias

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging and Inflammation: Translational Innovations

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital and Misc.

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Mechanisms and Models of Myeloid Malignancy

Oral and Poster Abstracts

613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML– Molecular Targets, Ethnicity, and AI

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Therapies for ALL

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant

Oral and Poster Abstracts

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy

Oral and Poster Abstracts

627. Aggressive Lymphomas: Clinical and Epidemiological: Uncommon Aggressive NHL

Oral and Poster Abstracts

631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Oncogenic Drivers and Genetic Models

Oral and Poster Abstracts

637. Myelodysplastic Syndromes – Clinical and Epidemiological: Genomic Classification and Prognostication of MDS

Oral and Poster Abstracts

652. Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma

Oral and Poster Abstracts

653. Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma

Oral and Poster Abstracts

703. Cellular Immunotherapies: Basic and Translational: Evaluating Strategies to Enhance Cellular Immunotherapies

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas

Oral and Poster Abstracts

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real World Evidence

Oral and Poster Abstracts

711. Cell Collection and Processing: Hematopoietic Stem/Progenitor Cells Graft and Immune Effector Cells

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Expanding the Donor Pool

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Donor and Conditioning Regimen Selection

Oral and Poster Abstracts

801. Gene Therapies: The Long and the Short of Clinical Trials in Blood Disorders

Oral and Poster Abstracts

904. Outcomes Research – Non-Malignant Conditions: Blending the Old With the New: Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease

Oral and Poster Abstracts

905. Outcomes Research – Lymphoid Malignancies: Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma

Oral and Poster Abstracts

ASH Guidelines on Venous Thromboembolism (VTE): What's New

Special-Interest Sessions

Special Symposium on the Basic Science in Hemostasis and Thrombosis

Scientific Symposia

ASH Hemostasis and Thrombosis Community Networking Reception (for in-person participants)

Special-Interest Sessions

Poster Hall Reception (for in-person participants)

Events

Poster Session III - Presentations (for in-person participants)

Events

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III

Oral and Poster Abstracts

102. Iron Homeostasis and Biology: Poster III

Oral and Poster Abstracts

112. Thalassemia and Globin Gene Regulation: Poster III

Oral and Poster Abstracts

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III

Oral and Poster Abstracts

114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

201. Granulocytes, Monocytes, and Macrophages: Poster III

Oral and Poster Abstracts

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III

Oral and Poster Abstracts

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III

Oral and Poster Abstracts

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

321. Coagulation and Fibrinolysis: Basic and Translational: Poster III

Oral and Poster Abstracts

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

401. Blood Transfusion: Poster III

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging and Inflammation: Poster III

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: Poster III

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Poster III

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Poster III

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Poster III

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III

Oral and Poster Abstracts

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III

Oral and Poster Abstracts

618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III

Oral and Poster Abstracts

621. Lymphomas: Translational—Molecular and Genetic: Poster III

Oral and Poster Abstracts

622. Lymphomas: Translational–Non-Genetic: Poster III

Oral and Poster Abstracts

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III

Oral and Poster Abstracts

627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

636. Myelodysplastic Syndromes—Basic and Translational: Poster III

Oral and Poster Abstracts

637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III

Oral and Poster Abstracts

652. Multiple Myeloma: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

653. Multiple Myeloma: Prospective Therapeutic Trials: Poster III

Oral and Poster Abstracts

654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: Poster III

Oral and Poster Abstracts

703. Cellular Immunotherapies: Basic and Translational: Poster III

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III

Oral and Poster Abstracts

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III

Oral and Poster Abstracts

711. Cell Collection and Processing: Poster III

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III

Oral and Poster Abstracts

731. Autologous Transplantation: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III

Oral and Poster Abstracts

801. Gene Therapies: Poster III

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Poster III

Oral and Poster Abstracts

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III

Oral and Poster Abstracts

901. Health Services and Quality Improvement - Non-Malignant Conditions: Poster III

Oral and Poster Abstracts

902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster III

Oral and Poster Abstracts

903. Health Services and Quality Improvement –Myeloid Malignancies: Poster III

Oral and Poster Abstracts

904. Outcomes Research—Non-Malignant Conditions: Poster III

Oral and Poster Abstracts

905. Outcomes Research—Lymphoid Malignancies: Poster III

Oral and Poster Abstracts

906. Outcomes Research—Myeloid Malignancies: Poster III

Oral and Poster Abstracts

ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)

Special-Interest Sessions

Women In Hematology Networking Event (for in-person participants)

Special-Interest Sessions

Registration at the Convention Center (for in-person participants)

Events

Learn, Engage, and Relax in ASH Central (for in-person participants)

Events

Morning Coffee and Tuesday General Sessions (for in-person participants)

Events

Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals followed by ASH Bylaws Vote

General Sessions

Late-Breaking Abstracts Session

General Sessions

Presidential Symposium

General Sessions

Best of ASH

General Sessions

Business Meeting and Ceremonial Passing of the ASH President's Gavel

General Sessions

Binge-Watch Content on the Virtual Platform

Events

ASH Poster Walk on Genetic Mutations in Myeloma and Leukemia

ASH Poster Walks

ASH Poster Walk on What's Hot in Sickle Cell Disease Clinical Research in 2023

ASH Poster Walks

Binge-Watch Content on the Virtual Platform

Events

ASH Poster Walk on Diversity, Equity and Inclusion(DEI) in Hematology

ASH Poster Walks

ASH Poster Walk on Time to Examine Time Toxicity in Hematology

ASH Poster Walks

Binge-Watch Content on the Virtual Platform

Events

65th ASH Annual Meeting & Exposition

Wednesday, December 6, 2023

9:00 AM-11:55 PM

Thursday, December 7, 2023

1:00 AM-11:55 PM

5:30 AM-10:00 PM

3:00 PM-7:00 PM

Friday, December 8, 2023

5:30 AM-10:00 PM

7:00 AM-10:00 AM

7:00 AM-6:00 PM

9:00 AM-12:00 PM

11:00 AM-2:00 PM

2:00 PM-5:00 PM

Scientific Workshops

3:00 PM-6:00 PM

7:00 PM-10:00 PM

Saturday, December 9, 2023

7:00 AM-7:45 AM

7:00 AM-6:00 PM

8:00 AM-9:00 AM

9:00 AM-9:30 AM

9:00 AM-7:30 PM

9:05 AM-9:15 AM

9:15 AM-9:25 AM

9:30 AM-10:45 AM

9:30 AM-11:00 AM

10:00 AM-11:00 AM

11:00 AM-11:30 AM

11:00 AM-12:00 PM

11:00 AM-12:30 PM

11:00 AM-5:00 PM

11:05 AM-11:15 AM

11:15 AM-12:15 PM

11:20 AM-11:30 AM

11:30 AM-12:30 PM

11:35 AM-11:45 AM

12:30 PM-1:30 PM

1:30 PM-1:45 PM

1:30 PM-2:00 PM

1:35 PM-1:45 PM

1:45 PM-1:55 PM

2:00 PM-3:15 PM

2:00 PM-3:30 PM

3:30 PM-3:45 PM

3:30 PM-4:00 PM

3:35 PM-3:45 PM

3:45 PM-3:55 PM

4:00 PM-5:00 PM

4:00 PM-5:15 PM

4:00 PM-5:30 PM

4:00 PM-5:35 PM

5:00 PM-5:30 PM

5:30 PM-7:30 PM

6:30 PM-8:00 PM

8:00 PM-9:00 PM

Sunday, December 10, 2023

7:00 AM-9:00 AM

7:00 AM-5:00 PM

7:00 AM-6:00 PM

7:30 AM-9:30 AM

8:00 AM-9:00 AM

9:00 AM-9:30 AM

9:00 AM-8:00 PM

9:05 AM-9:15 AM

9:15 AM-9:25 AM

9:30 AM-10:45 AM

9:30 AM-11:00 AM

9:30 AM-11:05 AM

10:00 AM-11:00 AM

10:00 AM-5:00 PM

11:00 AM-11:30 AM

11:00 AM-12:30 PM

11:05 AM-11:15 AM

11:15 AM-12:15 PM

11:15 AM-12:30 PM

11:20 AM-11:30 AM

11:30 AM-12:30 PM

11:35 AM-11:45 AM

12:00 PM-1:30 PM